Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.19
SPNC's Cash to Debt is ranked lower than
72% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. SPNC: 0.19 )
Ranked among companies with meaningful Cash to Debt only.
SPNC' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 0.19

Equity to Asset 0.32
SPNC's Equity to Asset is ranked lower than
65% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 0.52 vs. SPNC: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
SPNC' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.89
Current: 0.32

0.32
0.89
F-Score: 1
Z-Score: 1.78
M-Score: -2.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -25.44
SPNC's Operating margin (%) is ranked lower than
54% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -10.56 vs. SPNC: -25.44 )
Ranked among companies with meaningful Operating margin (%) only.
SPNC' s 10-Year Operating margin (%) Range
Min: -34.35   Max: 4.35
Current: -25.44

-34.35
4.35
Net-margin (%) -28.08
SPNC's Net-margin (%) is ranked lower than
54% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -12.96 vs. SPNC: -28.08 )
Ranked among companies with meaningful Net-margin (%) only.
SPNC' s 10-Year Net-margin (%) Range
Min: -32.33   Max: 23.17
Current: -28.08

-32.33
23.17
ROE (%) -36.96
SPNC's ROE (%) is ranked lower than
56% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -14.48 vs. SPNC: -36.96 )
Ranked among companies with meaningful ROE (%) only.
SPNC' s 10-Year ROE (%) Range
Min: -44.49   Max: 29.8
Current: -36.96

-44.49
29.8
ROA (%) -15.12
SPNC's ROA (%) is ranked lower than
54% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -7.12 vs. SPNC: -15.12 )
Ranked among companies with meaningful ROA (%) only.
SPNC' s 10-Year ROA (%) Range
Min: -28.33   Max: 18.65
Current: -15.12

-28.33
18.65
ROC (Joel Greenblatt) (%) -85.14
SPNC's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: -26.51 vs. SPNC: -85.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPNC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -183.56   Max: 27.96
Current: -85.14

-183.56
27.96
Revenue Growth (3Y)(%) 10.00
SPNC's Revenue Growth (3Y)(%) is ranked higher than
86% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SPNC: 10.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPNC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.7   Max: 29.4
Current: 10

-3.7
29.4
» SPNC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SPNC Guru Trades in Q2 2014

Ron Baron 60,480 sh (+63.55%)
Jim Simons Sold Out
» More
Q3 2014

SPNC Guru Trades in Q3 2014

Ron Baron 309,727 sh (+412.11%)
» More
Q4 2014

SPNC Guru Trades in Q4 2014

Steven Cohen 70,900 sh (New)
Ron Baron 270,280 sh (-12.74%)
» More
Q1 2015

SPNC Guru Trades in Q1 2015

Steven Cohen 559,000 sh (+688.43%)
Ron Baron 862,579 sh (+219.14%)
» More
» Details

Insider Trades

Latest Guru Trades with SPNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on The Spectranetics Corp

Baron Funds Comments on Spectranetics Corporation - Feb 26, 2014

The Spectranetics Corporation (SPNC) is a manufacturer of medical devices that assist in the treatment of peripheral arterial disease and also with the removal of coronary leads used for implanted devices such as pacemakers and defibrillators. Shares were up 46% in the quarter. Most of the company's devices use disposable products that lead to a highly recurring revenue stream. The company is on the verge of opening up large new markets with the expected 2014 approval of a new laser based device that can open up arteries that have previously been stented. If approved, it will be the only device on the market that has this capability.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
Forward P/E 357.14
SPNC's Forward P/E is ranked higher than
53% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SPNC: 357.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 7.40
SPNC's P/B is ranked lower than
88% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. SPNC: 7.40 )
Ranked among companies with meaningful P/B only.
SPNC' s 10-Year P/B Range
Min: 0.78   Max: 13.1
Current: 7.4

0.78
13.1
P/S 4.51
SPNC's P/S is ranked lower than
76% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SPNC: 4.51 )
Ranked among companies with meaningful P/S only.
SPNC' s 10-Year P/S Range
Min: 0.69   Max: 8.47
Current: 4.51

0.69
8.47
Current Ratio 3.10
SPNC's Current Ratio is ranked higher than
65% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. SPNC: 3.10 )
Ranked among companies with meaningful Current Ratio only.
SPNC' s 10-Year Current Ratio Range
Min: 1.4   Max: 8.52
Current: 3.1

1.4
8.52
Quick Ratio 2.39
SPNC's Quick Ratio is ranked higher than
65% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. SPNC: 2.39 )
Ranked among companies with meaningful Quick Ratio only.
SPNC' s 10-Year Quick Ratio Range
Min: 1.2   Max: 7.99
Current: 2.39

1.2
7.99
Days Inventory 144.81
SPNC's Days Inventory is ranked higher than
60% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 198.08 vs. SPNC: 144.81 )
Ranked among companies with meaningful Days Inventory only.
SPNC' s 10-Year Days Inventory Range
Min: 76.33   Max: 148.51
Current: 144.81

76.33
148.51
Days Sales Outstanding 63.64
SPNC's Days Sales Outstanding is ranked higher than
70% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 96.55 vs. SPNC: 63.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPNC' s 10-Year Days Sales Outstanding Range
Min: 48.49   Max: 111.77
Current: 63.64

48.49
111.77

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 32.40
SPNC's Price/DCF (Projected) is ranked higher than
61% of the 375 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SPNC: 32.40 )
Ranked among companies with meaningful Price/DCF (Projected) only.
SPNC' s 10-Year Price/DCF (Projected) Range
Min: 5.23   Max: 336.5
Current: 32.4

5.23
336.5
Price/Median PS Value 1.10
SPNC's Price/Median PS Value is ranked higher than
76% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SPNC: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
SPNC' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 1.84
Current: 1.1

0.18
1.84
Earnings Yield (Greenblatt) -4.80
SPNC's Earnings Yield (Greenblatt) is ranked lower than
56% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: -2.60 vs. SPNC: -4.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
SPNC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.8   Max: 31.1
Current: -4.8

-4.8
31.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SC7.Germany,
The Spectranetics Corp is incorporated under the laws of Delaware and formed in 1984. The Company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company has two operating segments that are identified on a geographic basis: U.S. Medical and International Medical. U.S. Medical and International Medical offer the same products and services but operate in different geographic regions, have different distribution networks and different regulatory environments. Its products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. Approximately 68% of its disposable product revenue is from products used in connection with its proprietary excimer laser system, the CVX-300. Its single-use laser catheters contain up to 250 small diameters, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its disposable products are develops in two categories: Vascular Intervention (VI) and Lead Management (LM). Vascular Intervention products include; support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions, drug delivery catheters for vascular delivery of drugs and diagnostic agents. Lead Management products include: excimer laser sheaths; non-laser sheaths; and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. Its competitors are manufacturers of products used in competing therapies within the peripheral and coronary atherectomy markets, such as: atherectomy and thrombectomy, using mechanical methods to remove arterial blockages, balloon angioplasty and stents, specialty balloon angioplasty, bypass surgery and amputation. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA. FDA regulations govern.
» More Articles for SPNC

Headlines

Articles On GuruFocus.com
Baron Funds Comments on Spectranetics Corporation Feb 26 2014 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 08 2010 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 06 2009 
Spectranetics Corp. Reports Operating Results (10-Q) Aug 10 2009 
Spectranetics Corp. Reports Operating Results (10-Q) May 11 2009 
Spectranetics to Hold 2008 Fourth Quarter Financial Results Conference Call on February 19 Feb 12 2009 
Spectranetics Cross-Pilot Product Receives FDA Clearance Dec 15 2008 
Weekly CEO Buys Highlight: Spectranetics Corp., Noven Pharmaceuticals Inc., Dolan Media Company, Mod Sep 09 2008 

More From Other Websites
SPECTRANETICS CORP Files SEC form 8-K, Regulation FD Disclosure May 27 2015
4:12 pm Spectranetics announces that 12-month data from the EXCITE ISR clinical trial were... May 27 2015
EXCITE ISR Landmark Study Proves Durability at 12-Months, Findings Validate Safety and Superiority... May 27 2015
SPECTRANETICS CORP Financials May 15 2015
10-Q for The Spectranetics Corp. May 10 2015
SPECTRANETICS CORP Files SEC form 10-Q, Quarterly Report May 08 2015
4 Big-Volume Stocks to Trade for Breakouts May 04 2015
Spectranetics to Participate in Upcoming Investor Conferences Apr 30 2015
Spectranetics to Participate in Upcoming Investor Conferences Apr 30 2015
Nasdaq stocks posting largest percentage decreases Apr 29 2015
SPECTRANETICS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Apr 29 2015
Spectranetics upgraded by Northland Capital Apr 27 2015
Spectranetics (SPNC) Stock Slips Today on Weak Earnings Results Apr 24 2015
Spectranetics reports 1Q loss Apr 23 2015
Spectranetics reports 1Q loss Apr 23 2015
Spectranetics Accelerates Investment in Stellarex(TM) Drug- Coated Balloon Platform for Treatment of... Apr 23 2015
SPECTRANETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Apr 23 2015
Spectranetics Achieves First Quarter 2015 Revenue of $57.4 Million Apr 23 2015
Spectranetics Accelerates Investment in Stellarex(TM) Drug- Coated Balloon Platform for Treatment of... Apr 23 2015
Q1 2015 Spectranetics Corp Earnings Release - After Market Close Apr 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK